Bristol-Myers beats forecasts, as newer drugs deliver
(Reuters) - Bristol-Myers Squibb Co (BMY.N) reported better than expected quarterly sales and earnings, fueled by strong sales of newer treatments for leukemia, melanoma and diabetes.
The U.S. drugmaker on Thursday said it earned $925 million, or 56 cents per share, in the fourth quarter. That compared with $852 million, or 50 cents per share, in the year-earlier quarter.
(Reporting By Ransdell Pierson; Editing by Gerald E. McCormick)
- Body of Korean boy who raised ferry alarm believed found |
- Children's corpses reveal desperate attempts to escape Korean ferry |
- U.S. mother, officials settle suit over airport breast milk
- UPDATE 2-Body of Korean boy who raised ferry alarm believed found
- Explosion shuts large natural gas processing plant in Wyoming